# CENTER FOR DRUG EVALUATION AND RESEARCH

**APPLICATION NUMBER:** 

203441Orig1s000

PROPRIETARY NAME REVIEW(S)



# Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology Office of Medication Error Prevention and Risk Management

### **Proprietary Name Review--Final**

Date: November 19, 2012

Reviewer(s): Lissa C. Owens, PharmD

Division of Medication Error Prevention and Analysis

Team Leader: Lubna Merchant, M.S., PharmD

Division of Medication Error Prevention and Analysis

Drug Name(s) and Strength(s): Gattex (Teduglutide [rDNA origin]) for Injection

5 mg/vial

Application Type/Number: NDA 203441

Applicant/sponsor: NPS Pharmaceuticals


OSE RCM #: 2012-1866

\*\*\* This document contains proprietary and confidential information that should not be released to the public.\*\*\*



### **CONTENTS**

1	INTRODUCTION	. :
2	METHODS AND DISCUSSION	. :
3	CONCLUSIONS	. :
4	REFERENCES	_



### 1 INTRODUCTION

This re-assessment of the proposed proprietary name, Gattex is written in response to the anticipated approval of this NDA within 90 days from the date of this review. DMEPA found the proposed name, Gattex, acceptable in OSE Review RCM # 2011-4409 dated February 22, 2012.

#### 2 METHODS AND DISCUSSION

For re-assessments of proposed proprietary names, DMEPA searches a standard set of databases and information sources (see section 4) to identify names with orthographic and phonetic similarity to the proposed name that have been approved since the previous OSE proprietary name review. For this review we used the same search criteria described in OSE Review RCM # 2011-4409. We note that none of the proposed product characteristics were altered. However, we evaluated the previously identified names of concern considering any lessons learned from recent post-marketing experience, which may have altered our previous conclusion regarding the acceptability of the proposed proprietary name. The searches of the databases yielded no new names, thought to look or sound similar to Gattex and represent a potential source of drug name confusion.

Additionally, DMEPA searched the USAN stem list to determine if the name contains any USAN stems as of the last USAN updates. The Safety Evaluator did not identify any United States Adopted Names (USAN) stems in the proposed proprietary name, as of November 6, 2012. The Office of Prescription Drug Promotion OPDP re-reviewed the proposed name on October 4, 2012 and had no concerns regarding the proposed name from a promotional perspective.

### 3 CONCLUSIONS

The re-evaluation of the proposed proprietary name, Gattex, did not identify any vulnerabilities that would result in medication errors with any additional names. Thus, DMEPA has no objection to the proprietary name, Gattex, for this product at this time.

DMEPA considers this a final review; however, if approval of the NDA is delayed beyond 90 days from the date of this review, the Division of Gastroenterology and Inborn Errors Products should notify DMEPA because the proprietary name must be re-reviewed prior to the new approval date.

If you have further questions or need clarifications, please contact Franklin Stephenson, OSE project manager, at 301-796-3872.



### 4 REFERENCES

- 1. OSE Reviews: Siahpoushan, Manizheh., OSE RCM #2011-4409, Proprietary Name Review for Gattex (NDA 203441), February 22, 2012
- 2. Drugs@FDA (http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm)

Drugs@FDA contains most of the drug products approved since 1939. The majority of labels, approval letters, reviews, and other information are available for drug products approved from 1998 to the present. Drugs@FDA contains official information about FDA approved <a href="mailto:brand name">brand name</a>, <a href="mailto:generic drugs">generic drugs</a>, <a href="mailto:therapeutic biological products">therapeutic biological products</a>, <a href="mailto:prescription">prescription</a> and <a href="mailto:over-the-counter">over-the-counter</a> human drugs and <a href="mailto:discontinued drugs">discontinued drugs</a> and <a href="mailto:">Chemical Type 6</a>" approvals.

**3.** *USAN Stems* (http://www.ama-assn.org/ama/pub/physician-resources/medical-science/united-states-adopted-names-council/naming-guidelines/approved-stems.page?)

USAN Stems List contains all the recognized USAN stems.

4. Division of Medication Error Prevention and Analysis Proprietary Name Consultation Request

Compiled list of proposed proprietary names submitted to the Division of Medication Error Prevention and Analysis for review. The list is generated on a weekly basis from the Access database/tracking system.



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

### **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

### **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

